Literature DB >> 11761433

Endocrine inactive and gonadotroph adenomas: diagnosis and management.

M Losa1, P Mortini, R Barzaghi, A Franzin, M Giovanelli.   

Abstract

Endocrine inactive pituitary adenomas represent about one quarter of all pituitary tumors. By immunocytochemistry, most of these tumors are positive for intact gonadotropins and/or their subunits. Clinical presentation is usually secondary to mass effect symptoms, such as visual disturbances, headache, and hypopituitarism. Differential diagnosis is usually accomplished by neuroradiologic studies, even though in selected cases positron emission tomography and/or single photon emission tomography may aid to distinguish pituitary adenomas from other endocrine inactive lesions, such as meningiomas and craniopharyngiomas. Surgical management is usually considered the first choice treatment for patients with endocrine inactive pituitary adenomas because it is very effective in ameliorating symptoms of chiasmal compression and headache. Radical removal of the tumor, however, is difficult to obtain because of the frequent invasiveness into the cavernous sinus. Radiation therapy diminishes the likelihood of tumor recurrence, especially in patients with demonstrable tumor remnants after surgery. Medical therapy with dopaminergic drugs, somatostatin analogs, or gonadotropin-releasing hormone agonists or antagonists causes mild reduction of tumor size in few patients and, therefore, seems to be of limited value in the therapeutic management of patients with endocrine inactive pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761433     DOI: 10.1023/a:1012965617685

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  79 in total

1.  Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma.

Authors:  M Faggiano; T Criscuolo; L Perrone; C Quarto; A A Sinisi
Journal:  Acta Endocrinol (Copenh)       Date:  1983-02

2.  Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.

Authors:  A Klibanski; J L Jameson; B M Biller; W F Crowley; N T Zervas; J Rivier; W W Vale; H Bikkal
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

3.  Five-year follow-up of nonsecreting pituitary adenomas.

Authors:  B Petruson; K E Jakobsson; J Elfverson; B A Bengtsson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1995-03

4.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors:  U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

Review 5.  Management of nonfunctioning pituitary adenomas.

Authors:  G Sassolas; J Trouillas; C Treluyer; G Perrin
Journal:  Acta Endocrinol (Copenh)       Date:  1993-07

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).

Authors:  G Faglia; N Bazzoni; A Spada; M Arosio; B Ambrosi; F Spinelli; R Sara; C Bonino; F Lunghi
Journal:  J Clin Endocrinol Metab       Date:  1991-10       Impact factor: 5.958

8.  Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.

Authors:  D J Kwekkeboom; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-02       Impact factor: 3.478

9.  Recognition of gonadotroph adenomas in women.

Authors:  L Daneshdoost; T A Gennarelli; H M Bashey; P J Savino; R C Sergott; T M Bosley; P J Snyder
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

Review 10.  Imaging of pituitary tumours.

Authors:  W W De Herder; S W Lamberts
Journal:  Baillieres Clin Endocrinol Metab       Date:  1995-04
View more
  8 in total

Review 1.  Functional Gonadotroph Adenomas: Case Series and Report of Literature.

Authors:  David J Cote; Timothy R Smith; Courtney N Sandler; Tina Gupta; Tejus A Bale; Wenya Linda Bi; Ian F Dunn; Umberto De Girolami; Whitney W Woodmansee; Ursula B Kaiser; Edward R Laws
Journal:  Neurosurgery       Date:  2016-12       Impact factor: 4.654

2.  A non-functioning pituitary adenoma initially mimicking a microprolactinoma: The case for long-term follow-up of patients with mild hyperprolactinemia?

Authors:  M Losa; P Mortini; M Giovanelli
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

3.  A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome.

Authors:  Lukui Chen; William L White; Robert F Spetzler; Bainan Xu
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

Review 4.  The role of radiation therapy in the management of non-functioning pituitary adenomas.

Authors:  M Losa; P Picozzi; M Motta; M Valle; A Franzin; P Mortini
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

Review 5.  Prognostic indicators in pituitary tumors.

Authors:  Agustinus Suhardja; Kalman Kovacs; Oded Greenberg; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 4.056

6.  Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas.

Authors:  Edward F Chang; Michael E Sughrue; Gabriel Zada; Charles B Wilson; Lewis S Blevins; Sandeep Kunwar
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

Review 7.  Multiple endocrine neoplasia type I.

Authors:  Rasa Zarnegar; Laurent Brunaud; Orlo H Clark
Journal:  Curr Treat Options Oncol       Date:  2002-08

8.  Prediction of Long-term Post-operative Testosterone Replacement Requirement Based on the Pre-operative Tumor Volume and Testosterone Level in Pituitary Macroadenoma.

Authors:  Cheng-Chi Lee; Chung-Ming Chen; Shih-Tseng Lee; Kuo-Chen Wei; Ping-Ching Pai; Cheng-Hong Toh; Chi-Cheng Chuang
Journal:  Sci Rep       Date:  2015-11-05       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.